Patents by Inventor Ian A. Wilson

Ian A. Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10494438
    Abstract: The invention provides methods for identifying protein modulators (e.g., antibody agonists) of eukaryotic cells. The methods typically involve expressing a combinatorial agent library (e.g., via lentiviral vectors) inside a eukaryotic cell type (e.g., a mammalian cell) and then directly selecting for agents (e.g., antibodies) that are agonist of a target molecule (e.g., a signaling receptor) that modulates a phenotype of or elicits a cellular response in the cell. Some related methods involve co-culturing a cell expressing a combinatorial agent library and a second cell, and then selecting agents that modulate a phenotype of or elicit a cellular response in the second cell. Preferably, the agents are antibodies and are introduced into and expressed in the starting cells under conditions each individual cell expresses no more than 3 different members of the antibody library.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: December 3, 2019
    Assignee: The Scripps Research Institute
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Publication number: 20190048043
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 14, 2019
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Publication number: 20190002539
    Abstract: Broadly neutralizing antibodies against HIV-1 which specifically bind to gp120 of HIV-1, a method of preparing such antibodies and the use thereof are provided.
    Type: Application
    Filed: January 26, 2017
    Publication date: January 3, 2019
    Inventors: Yiming Shao, Jiang Zhu, Yuxing Li, Ian A. Wilson, Leopold Kong, Bin Ju, Linling He, Li Ren, Yajing Chen, Jiandong Liu
  • Patent number: 9999664
    Abstract: The invention relates to an immunogenic HIV-1 gp120 mini V3 loop, which is a truncated version of the full-length gp120 V3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides, which bind to broadly neutralizing antibodies.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: June 19, 2018
    Assignee: The Scripps Research Institute
    Inventors: Ian A. Wilson, Robyn L. Stanfield, Robert Pejchal
  • Publication number: 20180002425
    Abstract: The invention provides methods for identifying protein modulators (e.g., antibody agonists) of eukaryotic cells. The methods typically involve expressing a combinatorial agent library (e.g., via lentiviral vectors) inside a eukaryotic cell type (e.g., a mammalian cell) and then directly selecting for agents (e.g., antibodies) that are agonist of a target molecule (e.g., a signaling receptor) that modulates a phenotype of or elicits a cellular response in the cell. Some related methods involve co-culturing a cell expressing a combinatorial agent library and a second cell, and then selecting agents that modulate a phenotype of or elicit a cellular response in the second cell. Preferably, the agents are antibodies and are introduced into and expressed in the starting cells under conditions each individual cell expresses no more than 3 different members of the antibody library.
    Type: Application
    Filed: August 8, 2017
    Publication date: January 4, 2018
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Patent number: 9738719
    Abstract: Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: August 22, 2017
    Assignee: The Scripps Research Institute
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Publication number: 20150316561
    Abstract: Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.
    Type: Application
    Filed: August 16, 2013
    Publication date: November 5, 2015
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Publication number: 20140302081
    Abstract: The invention relates to an immunogenic HIV-1 gp120 mini V3 loop, which is a truncated version of the full-length gp120 V3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides, which bind to broadly neutralizing antibodies.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 9, 2014
    Applicant: The Scripps Research Institute
    Inventors: Ian A. Wilson, Robyn L. Stanfield, Robert Pejchal
  • Patent number: 8568693
    Abstract: The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: October 29, 2013
    Assignee: GE Healthcare AS
    Inventors: Antonios Danikas, Clifford Smith, Ian A Wilson
  • Patent number: 8095314
    Abstract: A new method and system for generating probabilities of objective values of hazards as a fine granularity grid in four dimensions (three spatial dimensions plus time) to be used by decision support and visualization tools. Utilizing the proposed system, proxies for hazard data received at different times and in different formats may be used as input data to a grid of intelligent software agents which generate a four dimensional matrix of probabilities of objective values of hazards. The method allows for proxies and/or subjective information on hazards that may arrive asynchronously and with coarse temporal and spatial accuracy to be converted into a standard fine granularity four dimensional hazard probability grid. The grid is created automatically, without the need for expert human interpretation, can provide visualization of the four dimensional hazard volumes and may be used directly by decision support tools without the need for expert human interpretation.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: January 10, 2012
    Assignee: Embry-Riddle Aeronautical University, Inc.
    Inventor: Ian A. Wilson
  • Publication number: 20110124842
    Abstract: The present invention relates to the structure of Fab 4E10, e.g., as a complex with herein identified peptide KGND, herein identified as a 4E10 mimetope on gp41, as determined by crystallographic techniques, and the confirmation that peptide KGND has a functional relevant conformation, as well as the determination of key residues on 4E10, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides which bind to Fab 4E10.
    Type: Application
    Filed: July 19, 2006
    Publication date: May 26, 2011
    Inventors: Florence M. Brunel, Dennis R. Burton, Rosa M.F. Cardoso, Philip E. Dawson, Sharon Ferguson, Ian A. Wilson, Michael B. Zwick
  • Publication number: 20110002849
    Abstract: The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo.
    Type: Application
    Filed: February 26, 2009
    Publication date: January 6, 2011
    Inventors: Antonios Danikas, Clifford Smith, Ian A. Wilson
  • Publication number: 20100250600
    Abstract: The invention features computer-assisted methods for identifying molecules which will bind to the EPO receptor and act as an erythropoietin (EPO) mimetic. Preferred EPO mimetics identified using the method of the invention act as agonists of the EPO receptor in one or more in vitro or in vivo biological assays of EPO activity.
    Type: Application
    Filed: October 23, 2009
    Publication date: September 30, 2010
    Inventors: Ian A. Wilson, Oded Livnah, Enrico A. Stura, Dana L. Johnson, Linda K. Jolliffe
  • Publication number: 20090119019
    Abstract: The invention features computer-assisted methods for identifying molecules which will bind to the EPO receptor and act as an erythropoietin (EPO) mimetic. Preferred EPO mimetics identified using the method of the invention act as agonists of the EPO receptor in one or more in vitro or in vivo biological assays of EPO activity.
    Type: Application
    Filed: September 18, 2007
    Publication date: May 7, 2009
    Inventors: Ian A. Wilson, Oded Livnah, Enrico A. Stura, Dana L. Johnson, Linda K. Jolliffe
  • Publication number: 20080208474
    Abstract: A new method and system for generating probabilities of objective values of hazards as a fine granularity grid in four dimensions (three spatial dimensions plus time) to be used by decision support and visualization tools. Utilizing the proposed system, proxies for hazard data received at different times and in different formats may be used as input data to a grid of intelligent software agents which generate a four dimensional matrix of probabilities of objective values of hazards. The method allows for proxies and/or subjective information on hazards that may arrive asynchronously and with coarse temporal and spatial accuracy to be converted into a standard fine granularity four dimensional hazard probability grid. The grid is created automatically, without the need for expert human interpretation, can provide visualization of the four dimensional hazard volumes and may be used directly by decision support tools without the need for expert human interpretation.
    Type: Application
    Filed: October 4, 2007
    Publication date: August 28, 2008
    Inventor: Ian A. Wilson
  • Publication number: 20080151876
    Abstract: A new system and method of operating VOIP connections without a server. The proposed system and method allows for communications between parties to be set up using an ad-hoc, peer-to-peer protocol. The communications can carry both voice encoded as data and data transmissions.
    Type: Application
    Filed: December 19, 2007
    Publication date: June 26, 2008
    Inventors: Ian A. Wilson, Mohammed Mahmoud
  • Patent number: 7272508
    Abstract: The invention features computer-assisted methods for identifying molecules which will bind to the EPO receptor and act as an erythropoietin (EPO) mimetic. Preferred EPO mimetics identified using the method of the invention act as agonists of the EPO receptor in one or more in vitro or in vivo biological assays of EPO activity.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: September 18, 2007
    Assignee: The Scripps Research Institute
    Inventors: Ian A. Wilson, Oded Livnah, Enrico A. Stura, Dana L. Johnson, Linda K. Jolliffe
  • Patent number: 5835382
    Abstract: The invention features computer-assisted methods for identifying molecules which will bind to the EPO receptor and act as an erythropoietin (EPO) mimetic. Preferred EPO mimetics identified using the method of the invention act as agonists of the EPO receptor in one or more in vitro or in vivo biological assays of EPO activity.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: November 10, 1998
    Assignee: The Scripps Research Institute
    Inventors: Ian A. Wilson, Oded Livnah, Enrico A. Stura, Dana L. Johnson, Linda K. Jolliffe